📖
Patiromer for the management of hyperkalaemia in patients receiving renin‐angiotensin‐aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
Javed Butler, Stefan D Anker, Tariq Jamal Siddiqi, Andrew J S Coats, Fabio Dorigotti, Gerasimos Filippatos, Tim Friede, Udo‐michael Göhring, Mikhail N Kosiborod, Lars H Lund, Marco Metra, Carol Moreno Quinn, Ileana L Piña, Fausto J Pinto, Patrick Rossignol, Peter Szecsödy, Peter Van Meer, Matthew Weir, Bertram Pitt

Patiromer for the management of hyperkalaemia in patients receiving renin‐angiotensin‐aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial

Science & Mathematics Published 2021 Verification Pending

Overview & Synopsis

Aims: In patients with current or a history of hyperkalaemia, treatment with renin-angiotensin-aldosterone system inhibitors (RAASi) is often compromised. Patiromer, a novel potassium (K+ ) binder, may improve serum K+ levels and adherence to RAASi. Methods: The DIAMOND trial will enrol ~820 patients with heart failure with reduced ejection fraction (HFrEF; ejection fraction ≤40%). Patients meeting the screening criteria will enter a single-blinded run-in phase where they will be started or continued on a mineralocorticoid receptor antagonist (MRA) titrated to 50 mg/day and other RAASi therapy to ≥50% target dose, and patiromer. Patiromer will be titrated up to a maximum three packs/day (8.4 g/pack) to achieve optimal doses of RAASi without hyperkalaemia. The run-in phase will last up to 12 weeks, following which patients will undergo double-blind randomization in a 1:1 ratio to receive either continued patiromer or placebo (patiromer withdrawal). The primary endpoint is the mean difference in serum K+ from randomization between patiromer and placebo arms. Secondary endpoints will include hyperkalaemia events with K+ value >5.5 mEq/L, durable enablement of MRA at target dose, investigator-reported adverse events of hyperkalaemia, hyperkalaemia-related clinical endpoints and an overall RAASi Use Score (using a 0-8-point scale) comprising all-cause death, occurrence of cardiovascular hospitalization or usage of comprehensive HF medication. Conclusion: The DIAMOND trial is designed to determine if patiromer can favourably impact K+ control in patients with HFrEF with hyperkalaemia or a history of hyperkalaemia leading to RAASi therapy compromise, and in turn improve RAASi use.

Indexed from repository: HAL Open Science (hal.science)
Loading document from verified source...
Keyboard Shortcuts: ← / → for pages • + / - for zoom • 0 to fit width Powered by Mozilla PDF.js v3.11

Document Information

Document Title Patiromer for the management of hyperkalaemia in patients receiving renin‐angiotensin‐aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial
Author / Organization Javed Butler, Stefan D Anker, Tariq Jamal Siddiqi, Andrew J S Coats, Fabio Dorigotti, Gerasimos Filippatos, Tim Friede, Udo‐michael Göhring, Mikhail N Kosiborod, Lars H Lund, Marco Metra, Carol Moreno Quinn, Ileana L Piña, Fausto J Pinto, Patrick Rossignol, Peter Szecsödy, Peter Van Meer, Matthew Weir, Bertram Pitt
Subject & Discipline Multidisciplinary Academic Open Research
Categories Science & Mathematics
Publication Year 2021
License / Rights Open Access / Creative Commons
Resource Verification Listed PDF (Verification Pending)
Original Host Website HAL Open Science (hal.science)
File Format application/pdf (Portable Document Format)
Language EN
Catalog ID DOC-156776
Original Source Link Visit Source Page on hal.science »